Catheter Precision, INC

Catheter Precision, Inc. has filed a Certificate of Designation for its Series C-4 Convertible Preferred Stock, detailing its terms and rights.

Catheter Precision, Inc. announced the closing of its Series C-3 Convertible Preferred Stock sale, raising $3.47 million for working capital and general corporate purposes.

Catheter Precision, Inc. announced a private placement transaction where it purchased shares of Volato Group, Inc. for $1 million.

Catheter Precision announced a 200% year-over-year revenue increase to $432,000 for Q1 2026, driven by its medical device segment and the newly acquired aviation platform, Flyte, while also reducing its net loss.

Catheter Precision, Inc. announced the closing of its Series C-2 Convertible Preferred Stock offering, raising $3,470,000 in gross proceeds.

Catheter Precision shareholders approved the issuance of shares for multiple preferred stock series and a reverse stock split.

Catheter Precision, Inc. reported its Q1 2026 financial results, highlighting increased revenues from its cardiac electrophysiology and private aviation segments following the acquisition of FLYTE.

Catheter Precision reported increased Q3 2025 revenues driven by LockeT sales but faces substantial doubt about its ability to continue as a going concern due to recurring losses and negative cash flows.

Catheter Precision, Inc. reported increased net losses and negative cash flows for the first half of 2025, despite strategic acquisitions and capital raising efforts, raising substantial doubt about its ability to continue as a going concern.

Catheter Precision's Q1 2025 results reveal increased revenue offset by higher expenses, leading to a net loss and raising concerns about the company's ability to continue as a going concern.

Catheter Precision's Q3 2024 report reveals a net loss of $4.12 million, ongoing financial challenges, and strategic shifts following a merger, while also highlighting new product sales and a recent public offering.

Catheter Precision's Q2 2024 results reveal continued operating losses and a substantial doubt about the company's ability to continue as a going concern.

Catheter Precision, a medical device company, reported recurring losses and substantial doubt about its ability to continue as a going concern, while actively raising capital and diversifying into private aviation.

Catheter Precision files an amendment to its 2024 annual report to include previously omitted information regarding related party transactions.

Catheter Precision's 2024 10-K filing highlights continued losses, a need for additional capital, and ongoing efforts to commercialize its VIVO and LockeT products.

Catheter Precision's 10-K filing details its capital stock, including common and preferred shares, warrants, and anti-takeover provisions.

Catheter Precision Director James Joseph Caruso acquired 40,000 stock options with an exercise price of $1.15, signaling potential confidence in the company's future.

Catheter Precision's Chairman and CEO, David A. Jenkins, reported beneficial ownership of 340,000 Series M Common Stock Purchase Warrants with conflicting expiration dates.

Catheter Precision Director James Joseph Caruso converted Series X Convertible Preferred Stock into 41 shares of common stock.

Catheter Precision's Chairman and CEO, David A. Jenkins, converted Series X Convertible Preferred Stock into common stock, increasing his direct and indirect common stock holdings.

Director Andrew Arno acquired options to purchase 50,000 shares of Catheter Precision, Inc. common stock.

Catheter Precision, Inc. Director Martin J. Colombatto was granted 50,000 stock options with an exercise price of $0.18, vesting over three years.

Catheter Precision, Inc. calls a Special Meeting to approve significant preferred stock issuances, an acquisition, and a reverse stock split to meet NYSE American listing requirements and fund operations.

Catheter Precision, Inc. will hold a special meeting to vote on increasing authorized common stock by 733% to facilitate urgent financing needed to fund operations beyond January 2026.

Catheter Precision announces a September 10th record date for its October 10th special meeting of stockholders to approve increasing authorized shares and ratify the auditor.

Catheter Precision, Inc. is seeking shareholder approval for significant capital structure adjustments, including the issuance of millions of shares related to warrants and convertible preferred stock, and a potential reverse stock split, at its upcoming 2025 Annual Meeting.

Catheter Precision, Inc. has scheduled its 2025 Annual Meeting of Stockholders to vote on key proposals including the election of a director, the issuance of over 13 million shares, and a reverse stock split.

Catheter Precision, Inc. has approved the issuance of a common stock purchase warrant to Ladenburg Thalmann & Co., Inc. as partial compensation for services related to its May 2025 PIPE financing, pending stockholder approval.

Catheter Precision is registering for resale up to 10,695,962 shares of common stock held by selling stockholders, stemming from a recent warrant repricing.

Catheter Precision, Inc. has filed a registration statement to offer common stock units, pre-funded units, and underwriter warrants totaling $564,834.

Catheter Precision is undertaking a firm commitment public offering of common stock and pre-funded warrant units to raise capital for clinical trials, working capital, and general corporate purposes.

Catheter Precision, Inc. files an amendment to its Form S-1 registration statement to include exhibits related to a proposed offering of common stock and pre-funded warrants.

Catheter Precision is undertaking a firm commitment public offering to raise approximately $3.6 million to support operations, clinical trials, and working capital.

Catheter Precision, Inc. announces a firm commitment public offering of common stock and pre-funded warrants to raise approximately $5 million for operations, clinical trials, and debt repayment.

Catheter Precision, Inc. has filed an amended Schedule 13D revealing an updated beneficial ownership stake for CEO David Jenkins and related entities, alongside a new grant of 450,000 stock options to Mr. Jenkins.

Casey A. Jenkins and the Jenkins Family Charitable Institute have updated their beneficial ownership in Catheter Precision, Inc., increasing their aggregate stake to 9.9% and detailing recent warrant transactions and transfers.

SEG JETS SPV I, LLC has reported beneficial ownership of 1,065,620 shares of Catheter Precision, Inc. common stock, representing 9.79% of the class.

Catheter Precision, Inc. has filed a Schedule 13G reporting a 7.5% beneficial ownership stake in Volato Group, Inc. following a private placement.

Multiple C/M Capital entities and associated individuals have filed a Schedule 13G, reporting 0% beneficial ownership of Catheter Precision, Inc. common stock as of March 31, 2026.

Jonathan Juchno and affiliated entities disclose a combined 9.6% beneficial ownership stake in Catheter Precision, Inc. common stock.

Gregory Castaldo has disclosed a 7.5% beneficial ownership stake in Catheter Precision, Inc., holding 176,674 shares of common stock.

Joseph Reda has reported a 7.5% beneficial ownership stake in Catheter Precision, Inc., holding 176,674 shares of common stock.